Leukotriene modifiers: Novel therapeutic opportunities in asthma

Farmaco

Volumn 57, Issue 3, 2002, Pages 235-242

  Buccellati, Carola ^a   Fumagalli, Francesca ^a   Viappiani, Serena ^a   Folco, Giancarlo ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Asthma; Leukotriene modifiers; Novel therapeutic opportunity

Indexed keywords

1 [2 METHOXY 4 [(PHENYLSULFONYLAMINO)CARBONYL]BENZYL] 1H INDAZOLE 6 CARBAMIC ACID CYCLOPENTYL ESTER; 15 HYDROXYICOSATETRAENOIC ACID; 2 CYCLOPENTYL 2 [4 (2 QUINOLINYLMETHOXY)PHENYL]ACETIC ACID; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 (2 QUINOLINYLMETHOXY) 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 7 [3 (4 ACETYL 3 HYDROXY 2 PROPYLPHENOXY) 2 HYDROXYPROPOXY] 4 OXO 8 PROPYL 4H 1 BENZOPYRAN 2 CARBOXYLIC ACID; ALPHA PENTYL 3 (2 QUINOLYLMETHOXY)BENZYL ALCOHOL; ANTIASTHMATIC AGENT; BAY Y 1015; LEUKOTRIENE DERIVATIVE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LIPOXYGENASE INHIBITOR; QUINOLINE; ZAFIRLUKAST; INDOLE DERIVATIVE; LEUKOTRIENE; SLOW REACTING SUBSTANCE; TOLUENESULFONIC ACID DERIVATIVE;

ASTHMA; BIOSYNTHESIS; BRONCHOSPASM; BRONCHUS MUCUS; DISEASE SEVERITY; DRUG ACTIVITY; DRUG MECHANISM; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG SYNTHESIS; HUMAN; NONHUMAN; REVIEW; STRUCTURE ACTIVITY RELATION; ANIMAL; CHEMISTRY; DRUG ANTAGONISM; DRUG SCREENING; PHYSIOLOGY;

ANIMALS; ANTI-ASTHMATIC AGENTS; ASTHMA; DRUG EVALUATION, PRECLINICAL; HUMANS; INDOLES; LEUKOTRIENE ANTAGONISTS; LEUKOTRIENES; SRS-A; STRUCTURE-ACTIVITY RELATIONSHIP; TOSYL COMPOUNDS;

EID: 0036516857     PISSN: 0014827X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-827X(02)01209-0     Document Type: Review

References (28)

1. Samuelsson B., Dahlen S.E., Lindgren J.A., Rouzer C.A., Serhan C.N. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science. 237:1987;1171-1176.
2. Brown F.J. Discovery of Accolate™ [ICI 204,219]: a peptide leukotriene antagonist for asthma. Merluzzi V.J., Adams J. The Search for Anti-inflammatory Drugs. 1995;161-190 Birkhauser, Boston.
3. 4 analogues by proton NMR spectroscopy. J. Org. Chem. 48:1983;40-44.
4. Brown F.J., Yee Y.K., Cronk L.A., Hebbel K.C., Krell R.D., Snyder D.W. Evaluation of a series of peptidoleukotriene antagonists: synthesis and structure/activity relationships of 1,6-disubstituted indoles and indazoles. J. Med. Chem. 33:1990;1771-1781.
5. Bernstien P.R. The challenge of drug discovery: developing leukotriene antagonists. Holgate S.T., Dahlen S.E. SRS-A to Leukotrienes. 1997;171-187 Blackwell Science.
6. Krell R.D., Giles R.E., Yee Y.K., Snyder D.W. In vivo pharmacology of ICI 198,615: a novel, potent and selective peptide leukotriene antagonist. J. Pharmacol. Exp. Ther. 243:1987;557-564.
7. 4 antagonist activity of bicyclic and monocyclic cyclopentylurethane and cyclopentylacetamide N-arylsulfonyl amides. J. Med. Chem. 33:1990;2621-2629.
8. Yee Y.K., Brown F.J., Hebbel K.C., Cronk L.A., Snyder D.W., Krell R.D. Structure-activty relationships based on the peptide leukotriene receptor antagonist ICI 198,615: enhancement of potency. Ann. New York Acad. Sci. 524:1988;458-461.
9. Krell R.D., Aharony D., Buckner C.K., Keith R.A., Kusner E.J., Snyder D.W., Bernstein P.R., Matassa V.G., Yee Y.K., Brown F.J., et al. The preclinical pharmacology of ICI 204,219: a peptide leukotriene antagonist. Am. Rev. Respir. Dis. 141:1990;978-987.
10. Abraham W.M. The sheep as a model of the late asthmatic response. Raeburn D., Giembycz M.A. Airways Smooth Muscle: Modeling the Asthmatic Response In Vivo. 1996;171-189 Birkhauser, Basel.
11. 4 receptor antagonist, in subjects with bronchial asthma. Am. J. Respir. Crit. Care Med. 150:1994;618-623.
12. Suissa S., Dennis R., Ernst P., Sheehy O., Wood-Dauphinee S. Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma: a randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 126:1997;177-183.
13. Tashkin D.P., Nathan R.A., Howland W.C. III, Minkwitz M.C., Bonuccelli C.M. Efficacy of zafirlukast (Accolate®): exploratory subset data from three 13-week multicenter trials. Am. J. Respir. Crit. Care Med. 155:1997;A663.
14. Brock T.G., Paine R. III, Peters-Golden M. Localization of 5-lipoxygenase to the nucleus of unstimulated rat basophilie leukemia cells. J. Biol. Chem. 269:1994;22059-22066.
15. Kargman S., Vickers P.J., Evans J.F. A23187-induced transiocation of 5-lipoxygenase in osteosarcoma cells. J. Cell. Biol. 119:1992;1701-1709.
16. Coutts S.M., Khandwala A., van lnwegen R., Chakraborty U., Musser J., Bruens J., Jariwala N., Dally-Meade V., Ingram R., Pruss T., et al. Arymethyl phenyl ethers. A new class of specific inhibitors of 5-lipoxygenase. Bailey J.M. Prostaglandins, Leukotrienes and Lipoxins. Biochemistry, Mechanism of Action and Clinical Applications. 1985;627-637 Plenum Press, New York.
17. Muller-Peddinghaus R., Raddatz S. BAY X-1005-leukotriene synthesis inhibitor. Drugs Future. 20:1995;996-1000.
18. Hatzelmann A., Goosens J., Fruchtmann R., Mohrs K.H., Raddatz S., Muller-Peddinghaus R. Inversely-correlated inhibition of human 5-lipoxygenase activity by BAY X-1005 and other quinoline derivatives in intact cells and a cell-free system - implications for the function of 5-Iipoxygenase activating protein. Biochem. Pharmacol. 47:1994;2259-2268.
19. Matzke M., Beckermann B., Fruchtmann R., Fugmann B., Gardiner P.J., Goossens J., Hatzelmann A., Junge B., Keldenich J., Kohlsdorfer C., et al. Leukotriene synthesis inhibitors of the quinoline type: parameters for the optimization of efficacy. Eur. J. Med. Chem. 30:1995;441s-451s.
20. Gorenne I., Labat C., Gascard J.P., Norel X., Muller-Peddinghaus R., Mohrs K.H., Taylor W.A., Gardiner P.J., Brink C. (R)-2-[4-(Quinolin-2-yl- methoxy)phenylj-2-cyclopentyl] acetic acid (BAY X-1005), a potent leukotriene synthesis inhibitor: effects on anti-IgE challenge in human airways. J. Pharmacol. Exp. Ther. 268:1994;868-872.
21. Fruchtmann R., Mohrs K.H., Hatzelmann A., Raddatz S., Fugmann B., Junge B., Horstmann H., Muller-Peddinghaus R. In vitro pharmacology of BAY X-1005, a new inhibitor of leukotriene synthesis. Agents Actions. 38:1993;188-195.
22. Gardiner P.J., Cuthbert N.J., Francis H.P., Fitzgerald M.F., Thompson A.M., Carpenter T.G., Patel U.P., Newton B.B., Mohrs K., Muller-Peddinghaus R., et al. Inhibtion of antigen-induced contraction of guinea-pig airways by a leukotriene synthesis inhibitor, BAY X-1005. Eur. J. Pharmacol. 258:1994;95-102.
23. Joosten A.B., Muller-Peddinghaus R., van den Berg W.B. Effect of the leukotriene synthesis inhibitor BAY X-1005 on the murine zymosan-accelerated collagen-induced arthritis (ZymCIA). Inflamm. Res. 44:(Suppl. 3):1995;S261.
24. Rossoni G., Sala A., Berti F., Testa T., Buccellati C., Molta C., Muller-Peddinghaus R., Maclouf J., Folco G.C. Myocardial protection by the leukotriene synthesis inhibitor BAY X-1005: importance of transcellular biosynthesis of cysteinyl-leukotrienes. J. Pharmacol. Exp. Ther. 276:1996;335-341.
25. Horstmann R., Beckermann B., Boettcher M., Dietrich H., Lemm G., Seitz I., Fauler J. Clinical pharmacological investigations with the new leukotriene synthesis inhibitor BAY X-1005. Am. J. Respir. Crit. Care Med. 149:1994;A465.
26. Groen H., Moesker H.L., Leeuwenkamp O.R., Sollie F.A.E., Jonkman J.H.G. Non pharmacokinetic or pharmacodynamic interaction between theophyline and the leukotriene biosynthesis inhibitor BAY X-1005. J. Clin. Pharmacol. 36:1996;639-646.
27. Dahlen B., Kumlin M., Ihre E., Zetterstrom O., Dalhen S.E. Inhibiton of allergen induced airway obstruction and leukotriene generation in atopic asthmatic subjects by the leukotriene biosynthesis inhibitor BAY X-1005. Thorax. 52:1997;342-347.
28. Hamilton A.L., Watson R.M., Wyile G., O'Byrne P.M. Attenuation of early and late phase allergen-induced bronchoconstrction in asthmatic subjects by a 5-lipoxygenase activating protein antagonist, BAY X-1005. Thorax. 52:1997;348-354.